Importantly, 20–30% of r/r ALL patients who received CD19-targeted CAR T cells eventually progress with CD19-negative relapses [1,2,3,4,5], which prompts the development of “second-line” CAR T cells targeting additional B cell surface markers. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.